The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Every year we meet with the world’s top health officials and others at the World Health Assembly (WHA) in Geneva in May — to help shape decisions and policies that will impact the health of people in the countries where we work and beyond.